vs
CARRIAGE SERVICES INC（CSV）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
CARRIAGE SERVICES INC的季度营收约是MESA LABORATORIES INC的1.6倍（$105.5M vs $65.1M），CARRIAGE SERVICES INC净利率更高（11.6% vs 5.6%，领先6.1%），CARRIAGE SERVICES INC同比增速更快（8.0% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $6.2M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 1.0%）
怡和Cycle & Carriage有限公司是怡和集团在东南亚的投资控股公司，目前该集团持有其75%的股份，是怡和集团在东南亚区域开展资本布局与投资业务的核心平台。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CSV vs MLAB — 直观对比
营收规模更大
CSV
是对方的1.6倍
$65.1M
营收增速更快
CSV
高出4.3%
3.6%
净利率更高
CSV
高出6.1%
5.6%
自由现金流更多
MLAB
多$11.8M
$6.2M
两年增速更快
MLAB
近两年复合增速
1.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $105.5M | $65.1M |
| 净利润 | $12.3M | $3.6M |
| 毛利率 | 34.8% | 64.2% |
| 营业利润率 | 23.3% | 12.2% |
| 净利率 | 11.6% | 5.6% |
| 营收同比 | 8.0% | 3.6% |
| 净利润同比 | 24.5% | 316.6% |
| 每股收益（稀释后） | $0.76 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSVMLAB
| Q4 25 | $105.5M | $65.1M | ||
| Q3 25 | $102.7M | $60.7M | ||
| Q2 25 | $102.1M | $59.5M | ||
| Q1 25 | $107.1M | $62.1M | ||
| Q4 24 | $97.7M | $62.8M | ||
| Q3 24 | $100.7M | $57.8M | ||
| Q2 24 | $102.3M | $58.2M | ||
| Q1 24 | $103.5M | $58.9M |
净利润CSVMLAB
| Q4 25 | $12.3M | $3.6M | ||
| Q3 25 | $6.6M | $2.5M | ||
| Q2 25 | $11.7M | $4.7M | ||
| Q1 25 | $20.9M | $-7.1M | ||
| Q4 24 | $9.9M | $-1.7M | ||
| Q3 24 | $9.9M | $3.4M | ||
| Q2 24 | $6.3M | $3.4M | ||
| Q1 24 | $7.0M | $-254.6M |
毛利率CSVMLAB
| Q4 25 | 34.8% | 64.2% | ||
| Q3 25 | 35.3% | 61.5% | ||
| Q2 25 | 35.2% | 62.0% | ||
| Q1 25 | 35.3% | 61.8% | ||
| Q4 24 | 34.4% | 63.3% | ||
| Q3 24 | 35.2% | 61.3% | ||
| Q2 24 | 36.2% | 64.0% | ||
| Q1 24 | 36.0% | 62.1% |
营业利润率CSVMLAB
| Q4 25 | 23.3% | 12.2% | ||
| Q3 25 | 17.0% | 7.8% | ||
| Q2 25 | 23.5% | 5.1% | ||
| Q1 25 | 29.5% | 2.4% | ||
| Q4 24 | 21.6% | 9.2% | ||
| Q3 24 | 22.7% | 6.1% | ||
| Q2 24 | 18.0% | 9.6% | ||
| Q1 24 | 18.8% | -460.6% |
净利率CSVMLAB
| Q4 25 | 11.6% | 5.6% | ||
| Q3 25 | 6.4% | 4.1% | ||
| Q2 25 | 11.5% | 8.0% | ||
| Q1 25 | 19.5% | -11.4% | ||
| Q4 24 | 10.1% | -2.7% | ||
| Q3 24 | 9.8% | 5.9% | ||
| Q2 24 | 6.1% | 5.8% | ||
| Q1 24 | 6.7% | -432.2% |
每股收益（稀释后）CSVMLAB
| Q4 25 | $0.76 | $0.65 | ||
| Q3 25 | $0.41 | $0.45 | ||
| Q2 25 | $0.74 | $0.85 | ||
| Q1 25 | $1.34 | $-1.30 | ||
| Q4 24 | $0.62 | $-0.31 | ||
| Q3 24 | $0.63 | $0.63 | ||
| Q2 24 | $0.40 | $0.62 | ||
| Q1 24 | $0.45 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | $254.8M | $186.7M |
| 总资产 | $1.3B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CSVMLAB
| Q4 25 | $1.7M | $29.0M | ||
| Q3 25 | $1.2M | $20.4M | ||
| Q2 25 | $1.4M | $21.3M | ||
| Q1 25 | $4.6M | $27.3M | ||
| Q4 24 | $1.2M | $27.3M | ||
| Q3 24 | $1.3M | $24.3M | ||
| Q2 24 | $1.5M | $28.5M | ||
| Q1 24 | $1.7M | $28.2M |
总债务CSVMLAB
| Q4 25 | — | $68.4M | ||
| Q3 25 | — | $69.4M | ||
| Q2 25 | — | $70.3M | ||
| Q1 25 | — | $71.3M | ||
| Q4 24 | — | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益CSVMLAB
| Q4 25 | $254.8M | $186.7M | ||
| Q3 25 | $242.1M | $178.5M | ||
| Q2 25 | $235.4M | $172.5M | ||
| Q1 25 | $223.1M | $159.8M | ||
| Q4 24 | $208.6M | $155.2M | ||
| Q3 24 | $198.1M | $161.5M | ||
| Q2 24 | $187.9M | $150.7M | ||
| Q1 24 | $179.6M | $145.4M |
总资产CSVMLAB
| Q4 25 | $1.3B | $434.8M | ||
| Q3 25 | $1.3B | $430.4M | ||
| Q2 25 | $1.3B | $435.7M | ||
| Q1 25 | $1.3B | $433.3M | ||
| Q4 24 | $1.3B | $433.3M | ||
| Q3 24 | $1.3B | $454.1M | ||
| Q2 24 | $1.3B | $440.4M | ||
| Q1 24 | $1.3B | $446.8M |
负债/权益比CSVMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.1M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $6.2M | $18.0M |
| 自由现金流率自由现金流/营收 | 5.9% | 27.7% |
| 资本支出强度资本支出/营收 | 7.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.15× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $40.1M | $37.9M |
8季度趋势，按日历期对齐
经营现金流CSVMLAB
| Q4 25 | $14.1M | $18.8M | ||
| Q3 25 | $24.7M | $8.2M | ||
| Q2 25 | $8.1M | $1.9M | ||
| Q1 25 | $13.8M | $12.7M | ||
| Q4 24 | $9.3M | $18.1M | ||
| Q3 24 | $20.9M | $5.3M | ||
| Q2 24 | $2.2M | $10.7M | ||
| Q1 24 | $19.7M | $12.9M |
自由现金流CSVMLAB
| Q4 25 | $6.2M | $18.0M | ||
| Q3 25 | $18.0M | $7.1M | ||
| Q2 25 | $5.2M | $884.0K | ||
| Q1 25 | $10.6M | $11.9M | ||
| Q4 24 | $4.9M | $17.3M | ||
| Q3 24 | $16.2M | $3.5M | ||
| Q2 24 | $-1.4M | $9.9M | ||
| Q1 24 | $16.2M | $12.3M |
自由现金流率CSVMLAB
| Q4 25 | 5.9% | 27.7% | ||
| Q3 25 | 17.5% | 11.7% | ||
| Q2 25 | 5.1% | 1.5% | ||
| Q1 25 | 9.9% | 19.2% | ||
| Q4 24 | 5.0% | 27.6% | ||
| Q3 24 | 16.1% | 6.0% | ||
| Q2 24 | -1.4% | 16.9% | ||
| Q1 24 | 15.6% | 21.0% |
资本支出强度CSVMLAB
| Q4 25 | 7.5% | 1.1% | ||
| Q3 25 | 6.5% | 1.8% | ||
| Q2 25 | 2.8% | 1.7% | ||
| Q1 25 | 3.0% | 1.2% | ||
| Q4 24 | 4.5% | 1.3% | ||
| Q3 24 | 4.6% | 3.1% | ||
| Q2 24 | 3.5% | 1.5% | ||
| Q1 24 | 3.4% | 0.9% |
现金转化率CSVMLAB
| Q4 25 | 1.15× | 5.17× | ||
| Q3 25 | 3.76× | 3.32× | ||
| Q2 25 | 0.69× | 0.40× | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.11× | 1.54× | ||
| Q2 24 | 0.34× | 3.17× | ||
| Q1 24 | 2.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSV
| Propertyand Merchandise | $47.8M | 45% |
| Cemetery Interment Rights | $24.8M | 23% |
| Merchandise | $18.9M | 18% |
| Other Revenue | $10.2M | 10% |
| Other | $3.9M | 4% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
